Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05220722|
Recruitment Status : Recruiting
First Posted : February 2, 2022
Last Update Posted : October 21, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma||Drug: SD-101 Biological: Pembrolizumab Biological: Nivolumab Biological: Ipilimumab||Phase 1 Phase 2|
All patients will receive 2 cycles of SD-101. Each cycle consists of 3 consecutive weekly infusions and Cycles 1 and 2 are separated by one month. Escalating doses of SD-101 will be administered alone (Cohort A), together with pembrolizumab (Cohort B), and together with combined ipilimumab and nivolumab (Cohort C). Cohort B will begin dosing at the minimum anticipated biological effect level (MABEL (2mg SD-101)). Cohort C will begin one dose level below the MTD or optimal dose from Cohort B to optimize safety when adding CPI to SD-101.
Following determination of the recommended MTD or optimal dose of SD-101 and which checkpoint inhibitor (CPI) regimen(s) are tolerated, the study will progress to Phase 2. Patients in Phase 2 will receive the SD-101 dose selected from Phase 1b together with systemic single- or double-agent checkpoint blockade. The choice of single- or double-agent CPI therapy together with SD-101 for Phase 2 will consider safety data in addition to response rates from Cohorts B and C in Phase 1b.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||89 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||
Phase 1b: Escalating doses of SD-101 will be administered alone (Cohort A), together with pembrolizumab (Cohort B), or together with combined ipilimumab and nivolumab. Three weekly doses of SD-101 are delivered over two cycles via HAI using the Pressure Enabled Drug Delivery (PEDD) method of administration.
Phase 2: Three weekly infusions of SD-101 will be delivered via PEDD/HAI over two cycles at the dose selected from Phase 1b in combination with systemic single- or dual-agent checkpoint blockade.
|Masking:||None (Open Label)|
|Official Title:||A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma|
|Actual Study Start Date :||March 2, 2022|
|Estimated Primary Completion Date :||January 2023|
|Estimated Study Completion Date :||January 2025|
Three weekly doses of SD-101 given over two cycles via HAI using the PEDD method of administration.
SD-101 doses will be delivered via HAI using the PEDD method of administration.
During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
Other Name: Keytruda
During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
Other Name: Opdivo
During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
Other Name: Yervoy
- Phase 1b: To Determine the Safety of SD-101 Alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab [ Time Frame: 12 months ]As a measure of safety, adverse events will be graded according to CTCAE v5.0.
- Phase 1b: To Determine the Maximum Tolerable Dose (MTD) or Optimal Dose of SD-101 alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab [ Time Frame: 12 months ]A standard 3+3 dose-escalation design will be employed to determine the MTD or optimal dose.
- Phase 2: To Assess Overall Response Rate (ORR) [ Time Frame: 12 months ]As a measure of activity, ORR will be assessed. ORR will be assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
- Phase 1b: Assess Preliminary Efficacy in Terms of iRECIST for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, iRECIST will be utilized to determine ORR.
- Phase 1b: Assess Preliminary Efficacy in Terms of modified RECIST (mRECIST) for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, mRECIST will be utilized to determine ORR.
- Phase 1b: Assess Preliminary Efficacy in Terms of RECIST v1.1 for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, RECIST 1.1 will be utilized to determine hepatic-specific response rate (HRR).
- Phase 1b: Assess Preliminary Efficacy in Terms of RECIST v1.1 for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, RECIST 1.1 will be utilized to determine overall progression-free survival (PFS).
- Phase 1b: Assess Preliminary Efficacy in Terms of RECIST v1.1 for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, RECIST 1.1 will be utilized to determine clinical benefit (complete response [CR] + partial response [PR] + stable disease [SD]).
- Phase 2: To Assess Treatment-Emergent Adverse Events of the Chosen MTD or Optimal Dose of SD-101 in Combination with CPI [ Time Frame: 6 months ]As a measure of safety, adverse events will be graded according to CTCAE v5.0.
- Phase 2: Assess Efficacy in Terms of RECIST v1.1 for Immune Based Therapeutics [ Time Frame: 12 months ]As a measure of activity, RECIST 1.1 will be utilized to determine duration of response (DOR).
- Phase 2: To Assess Overall Survival (OS) [ Time Frame: 12 months ]As a measure of activity, OS will be assessed. The events for the assessment of 12-month OS are death events.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 99 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 18 years of age or older with locally advanced, metastatic or unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma, with the diagnosis confirmed by histologic or cytologic analysis or clinical features according to the American Association for the Study of Liver Diseases.
- Previously received 1 line of standard therapy for liver cancer and with persistent or progressive measurable disease, as defined by RECIST version 1.1, that is not amenable to curative therapies
- Performance status score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale (scores range from 0 to 5, with higher numbers reflecting greater disability)
- Designation of class A on the Child-Pugh liver function scale (a three-category scale [A, B, or C], with C indicating the most severe compromise of liver function)
- Adequate hematologic and organ function.
- Has histologically or cytologically confirmed HCC or ICC with liver-only or liver-dominant disease. Liver-dominant will be defined as intrahepatic disease representing the largest fraction of disease.
- Able to understand the study and provide written informed consent prior to any study procedures
- Has not received prior cytotoxic chemotherapy, targeted therapy, or external radiation therapy within 14 days prior to screening
Has not ever received prior embolic HAI therapy with permanent embolic material.
Note: Previous embolic HAI therapy with permanent embolic material will not be exclusionary if following this therapy, the target vessels are not occluded, and tumors are perfused based on the patient's screening imaging.
Prior surgical resection or radiofrequency ablation of oligometastatic liver disease is allowed. Liver lesions that received ablative therapies should not be considered target lesions unless they have clearly progressed since the therapy or have viable tumor on contrast enhanced MRI or CT.
- Has no prior history of or other concurrent malignancy unless the malignancy is clinically insignificant, no ongoing treatment is required, and the patient is clinically stable
- Has measurable disease in the liver according to RECIST v.1.1 criteria
- Has a life expectancy of >3 months at screening as estimated by the investigator
- Has a QTc interval ≤480 msec
- All associated clinically significant (in the judgment of the investigator) drug-related toxicity from previous cancer therapy must be resolved (to Grade ≤1 or the patient's pretreatment level) prior to study treatment administration (Grade 2 alopecia and endocrinopathies controlled on replacement therapy are allowed).
Has adequate organ function at screening as evidenced by:
- Platelet count >100,000/μL
- Hemoglobin ≥8.0 g/dL
- White blood cell count (WBC) >2,000/μL
- Serum creatinine ≤2.0 mg/dL unless the measured creatinine clearance is ≥30 mL/min calculated by Cockcroft-Gault formula.
- Total and direct bilirubin ≤2.0 × the upper limit of normal (ULN) and alkaline phosphatase ≤5 × ULN. For patients with documented Gilbert's disease, total bilirubin up to 3.0 mg/dL is allowed.
- ALT and AST ≤5 × ULN
- Prothrombin time/International Normalized Ratio (INR) or activated partial thromboplastin time (aPTT) test results at screening ≤1.5 × ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose for at least 4 weeks prior to the first dose of study intervention) Note: Laboratory tests with exclusionary results judged by the investigator as not compatible with the patient's clinical status may be repeated once for eligibility purposes.
Females of childbearing potential must be nonpregnant and nonlactating, or post-menopausal, and have a negative serum human chorionic gonadotropin (hCG) pregnancy test result at screening and a negative urine or serum pregnancy test prior to the first dose of study intervention.
- Females of childbearing potential must agree to abstain from sexual activity with nonsterilized male partners, or if sexually active with a nonsterilized male partner must agree to use highly effective methods of contraception from screening, throughout the study and agree to continue using such precautions for 100 days after the final dose of study intervention.
- Nonsterilized males who are sexually active with a female of childbearing potential must agree to use effective methods of contraception and avoid sperm donation from Day 1 throughout the study and for 30 days after the final dose of study intervention.
- Has received chemotherapy or an investigational agent within 14 days (or 5 half-lives, whichever is shorter) before screening.
- Has active, untreated brain metastasis.
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Has main portal vein thrombosis, or severe portal hypertension as defined by a history of variceal hemorrhage or active ascites accumulation refractory to medical management
- Has more than 2/3 parenchymal replacement by tumor of both liver lobes.
- Has Child-Pugh Class B or C cirrhosis.
Has experienced a Grade 3 or higher immune-related AE from prior CPI therapy.
Note: Patients who have experienced a Grade 3 immune-related AE from prior CPI therapy will not be excluded if that AE has since recovered to a Grade 1 for a minimum of 14 days.
- Is unable to be temporarily removed from chronic anticoagulation therapy.
- Has a history of bleeding disorders.
- Has active coronavirus disease 2019 (COVID-19), other severe infection, including a liver infection, within 2 weeks before the first dose of study drug, or uncontrolled human immunodeficiency virus (HIV) infection at screening.
- Has had bacterial pneumonia within 8 weeks of first dose of study drug.
- Has active, known, or suspected autoimmune disease or immune-mediated disease. Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger are not exclusionary.
- Is receiving systemic steroid therapy >10 mg of prednisone daily or equivalent or any other immunosuppressive medication at any dose level. Local steroid therapies (e.g., otic, ophthalmic, intra-articular or inhaled medications) are acceptable.
- Has significant concurrent or intercurrent illness, psychiatric disorder, or alcohol or chemical dependence that would, in the opinion of the Investigator and/or Medical Monitor, compromise their safety or compliance or interfere with interpretation of the study.
- Lactating women are excluded from study participation.
- Has previously received SD-101.
- Medical history of significant hypersensitivity, severe and unresolved immune-mediated reactions, severe infusion-related reactions, or allergic reaction to TLR9 agonists or CPI agents in the judgment of the investigator.
- Patients who were enrolled in the Phase 1b portion of the study will not be eligible for enrollment in Phase 2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05220722
|United States, New York|
|Columbia||Not yet recruiting|
|New York, New York, United States, 10032|
|Contact: Nurse Navigators 212-342-5162 email@example.com|
|Columbia University||Not yet recruiting|
|New York, New York, United States, 80045|
|Contact: McKenna Russen 720-848-8785 firstname.lastname@example.org|
|Principal Investigator: Karie Runcie, MD|
|United States, Rhode Island|
|Rhode Island Hospital||Not yet recruiting|
|Providence, Rhode Island, United States, 02903|
|Contact: Caitlyn Krar 401-444-4818 CKrar@Lifespan.org|
|Principal Investigator: Khaldoun Almhanna, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Kimberly D Ross, RN 713-794-1623 email@example.com|
|Principal Investigator: Milind Javle, MD|
|Responsible Party:||TriSalus Life Sciences, Inc.|
|Other Study ID Numbers:||
|First Posted:||February 2, 2022 Key Record Dates|
|Last Update Posted:||October 21, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action